by Gus Iversen
, Editor in Chief | May 03, 2019
HCB News: Who would be the ideal candidates to undergo DeHCA imaging?
Mammography shows limited efficiency on dense breasts, which is not the case with DeHCA L&S. Therefore, the initial and ideal candidates to undergo DeHCA L&S examination are dense-breast women, typically young women today not considered by national screening plans. We should not forget that dense breast is considered a risk factor and characterizes almost all women in pre-menopausal status and about the 25% of women in post-menopausal status, with trend to increase with the increase of wellness. This percentage is even higher in most Asian countries.
Furthermore, breast glandular tissue has a high radiosensitivity to the ionizing radiations used with mammography, particularly in premenopausal women. DeHCA L&S does not emit any ionizing radiation.
HCB News: What stage of development is the system in?
Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.
At present, we are validating the device in a two-site trial. Two DeHCA L&S are installed at the European Institute of Oncology (IEO) and at the S. Raffaele Hospital (HSR), both in Milan (Italy). In parallel, we are continuing testing DeHCA L&S on volunteers at our lab. We plan to go to market in 2020.
HCB News: In terms of lowering costs and improving outcomes, what does DeHCA Light & Sound fit into the healthcare ecosystem?
The adoption of DeHCA L&S would lead to important savings in both direct and indirect costs of the healthcare ecosystem. This because the early detection ability will lead to less and lighter surgical interventions, softer radiant and drug therapies, reduced costs for physical rehabilitation and psychological support, shorter duration of inability to work due to surgery recovery and weakening treatments, more efficient monitoring of treatments and follow-up.
The economic benefits of the introduction of DeHCA L&S in the clinical practice, can be estimated in billions of euros per year, considering that in the western world almost one third of new tumors are found on women too young to participate to a structured screening program because the current screening methods would prove ineffective. We expect that DeHCA L&S examination will permit to diagnose breast cancer in this specific population, at stage 0-1 rather than at higher stages.
HCB News: Are you working with any hospitals on the system through clinical trials or other collaborations? If so, what kind of work is being done and what do you have planned for the future?
As said, when talking of the present development stage, we are actually validating DeHCA L&S in a two-site clinical trial at IEO (European Institute of Oncology) and HSR (Hospital S. Raffaele), two of the most reputed oncology centers in Italy.